This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
By Kurt R. Karst The FDA Reduction-in-Force (Termination)or RIF(T)announced last week has resulted in countless stories in the press and on personal LinkedIn accounts from those RIFd. As the dust begins to settle and we all assess what this means for the future of FDA and the public health, generally, this blogger wanted to call out one particular division in the Office of Generic Drugs (OGD), funded by user fees under the Generic Drug User Fee Amendments (GDUFA), that was eradicated and what t
Last week’s layoffs across the Department of Health and Human Services left a significant casualty in the vast ecosystem of government-backed science: an entire division focused on researching pain. The reduction in force enacted last week by Health Secretary Robert F. Kennedy Jr. eliminated all but one full-time position, out of roughly a dozen, within the National Institutes of Health Office of Pain Policy and Planning, a unit devoted to coordinating pain-related research across t
A digital self-assessment tool designed to help hospital pharmacy teams take practical action to support sustainability and reduce the environmental impact of pharmacy services, pharmaceutical care and medicines, while supporting patient care, has been launched by the Royal Pharmaceutical Society (RPS). The long-awaited RPS Greener Pharmacy Guide and Toolkit provides prompts to introduce more sustainable practices to reduce emissions, improve patient care, prevent ill health, tackle medicines wa
If you’re looking for an effective contraceptive method without the hassle of taking medicine daily, your healthcare provider may recommend an alternative method of birth control like NuvaRing (etonogestrel-ethinyl estradiol). The hormonal contraceptive is a flexible ring that is inserted in the vagina once every four weeks to prevent pregnancy.
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
GSK has agreed to develop novel medicines for neurodegenerative diseases, as part of a global licensing agreement with ABL Bio Inc, for up to 2.075 billion. This is subject to certain milestone payments across multiple potential programmes.The licensing deal will utilise ABL Bios blood-brain barrier shuttle platform Grabody-B, to advance multiple programmes across therapeutic modalities including antibody , polynucleotide or oligonucleotides, such as siRNA and ASOs.
I recently came across a reel on Instagram that I haven’t been able to stop thinking about since I saw it. A pastor in Texas stood before his congregation and proudly announced that their school had the lowest vaccination rate in the state. With balloons and celebratory T-shirts, he praised their community for what he called “freedom of health.
The Scottish Medicines Consortium (SMC) has accepted the use of Ipsens Iqirvo (elafibranor) in NHS Scotland for the treatment of primary biliary cholangitis (PBC), a rare liver disease. This marks the first new medicine for PBC to be accepted by the medical body in nearly a decade. Iqirvo is a peroxisome proliferator activated receptor (PPAR) […] The post Ipsens Iqirvo approved for use in NHS Scotland to treat rare liver disease appeared first on Pharmafile.
Signup to get articles personalized to your interests!
Pharmacy Technician Pulse brings together the best content for pharmacy technicians from the widest variety of industry thought leaders.
The Scottish Medicines Consortium (SMC) has accepted the use of Ipsens Iqirvo (elafibranor) in NHS Scotland for the treatment of primary biliary cholangitis (PBC), a rare liver disease. This marks the first new medicine for PBC to be accepted by the medical body in nearly a decade. Iqirvo is a peroxisome proliferator activated receptor (PPAR) […] The post Ipsens Iqirvo approved for use in NHS Scotland to treat rare liver disease appeared first on Pharmafile.
Editor’s note: This story contains a description of self-harm. Oncologist Mark Lewis has never had much of a poker face. When he walked into his cancer patient’s visit in 2022, he was wearing a big smile: The nodules in his patient’s lungs, he saw in the radiology report, were shrinking in response to treatment. His patient, though, was already upset.
High Force Research has announced that it has appointed Nathalie Huther as its first chief commercial officer (CCO) following the companys recent management buyout (MBO). This forms an important part of its business development and market expansion strategy. Huther will lead High Forces research commercial strategy, and brings a wealth of experience in commercial leadership […] The post High Force Research appoints Nathalie Huther as chief commercial officer appeared first on Pharmafile.
You’re reading the web edition of D.C. Diagnosis, STAT’s twice-weekly newsletter about the politics and policy of health and medicine. Sign up here to receive it in your inbox on Tuesdays and Thursdays. STAT is cutting the price of an annual subscription in half. Click here for details , and send news and tips to John.Wilkerson@statnews.com or via Signal at John_Wilkerson.07.
ELRIG, a non-profit volunteer-led organisation dedicated to the drug discovery community, has appointed Del Trezise as chair of the board. He succeeds Melanie Leveridge, who completed her four-year term as chair. He will lead ELRIGs mission to deliver highly accessible scientific meetings and conferences. It serves a global network of over 22,000 life sciences professionals. […] The post ELRIG appoints Del Trezise as chair appeared first on Pharmafile.
Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.
Process analytical technology (PAT), namely at-line, online or inline instruments, may be represented by univariate sensors or more complex analysers and systems resulting in multivariate datasets. These can be pivotal for achieving high precision, efficiency and control, as well as continuous and automated manufacturing. Here we provide an overview of the tasks involved in implementing PAT in a GMP environment, as well as opportunities for organisations to consider in the face of common challen
Tuberculosis infects more than a quarter of the world’s population, kills more than 1 million people per year, and is still a scourge at home. It has never disappeared from the United States, and there was even a recent cluster of cases in Boston, according to Sarah Fortune , a Harvard scientist leading one of the world’s preeminent tuberculosis research programs.
In a comprehensive review, researchers aimed to explore seasonality, environmental factors, and the genetic and epigenetic mechanisms of patients living with psoriasis vulgaris.
Top of the morning to you, and a fine one it is. Blue skies and comfortable breezes are enveloping the Pharmalot campus, where the official mascots are dozing in their respective corners and assorted wildlife can be seen bounding about the grounds. As for us, we are engaged in the usual rituals — firing up the coffee kettle in order to brew a cup of stimulation (the choice today is pecan bourbon) and foraging for items of interest.
Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist
What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.
In a review of skin inflammations link to food allergen sensitivity, researchers explored how patients with atopic dermatitis may be more susceptible to the development of food allergies.
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Good morning. I’m writing to you from San Diego, where STAT held an event during the American Academy of Neurology annual meeting this past weekend. We’ll get into a highlight from the event below, along with all the other biotech news today.
Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.
The HERCULES trial demonstrates tolebrutinib's potential to slow disability progression in non-relapsing secondary progressive multiple sclerosis, offering a new treatment option for patients with limited therapeutic choices.
In part 3 of our interview with Jenny Markell, BA, she discussed drug advertising trends among Alzheimers disease drugs and how FDA suggestions are not necessarily followed.
Small changes in blood pressure and pulse were shown in patients of all ages, and the authors suggested that these are monitored carefully in patients being treated for ADHD.
There were no statistically significant differences between cognitive behavioral therapy and mindfulness-based therapy in reducing the dosage for chronic lower back pain.
Five years ago, Michelle Werner received her son’s Duchenne muscular dystrophy diagnosis with fear and desperation. Now, as CEO of Alltrna, she’s finding ways to turn those feelings into a better way of treating rare diseases.
Consumers are using their insurers' websites, mobile apps and other digital platforms in greater numbers, but their experiences often fall short of expectations, according to a new report.
Get your daily dose of health and medicine every weekday with STAT’s free newsletter Morning Rounds. Sign up here. Good morning. In case you missed it yesterday, we have a winner for this year’s STAT Madness competition. From the same institution as last year — is that a dynasty I see forming?
We organize all of the trending information in your field so you don't have to. Join 5,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content